Takeda Pharmaceutical (TKPHF) Asset Writedowns and Impairment (2018 - 2026)

Takeda Pharmaceutical's Asset Writedowns and Impairment history runs 9 years deep, the most recent figure standing at $324.7 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 27.47% year-over-year to $324.7 million; the TTM figure through Mar 2026 stood at $966.1 million (up 38.73% YoY), while the FY2026 annual figure was $968.0 million, up 38.42% from the prior year.
• Asset Writedowns and Impairment was $324.7 million for Q1 2026 at Takeda Pharmaceutical, up from $49.7 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $823.1 million in Q3 2023 to a low of $14.2 million in Q4 2024.
• Historically, Asset Writedowns and Impairment has averaged $207.2 million across 5 years, with a median of $110.1 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Asset Writedowns and Impairment jumped 22639.3% in 2022, then slumped 91.8% in 2024.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $42.6 million in 2022, then gained by 20.33% to $51.3 million in 2023, then tumbled by 72.26% to $14.2 million in 2024, then soared by 249.41% to $49.7 million in 2025, then surged by 553.52% to $324.7 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $324.7 million (Q1 2026), $49.7 million (Q4 2025), and $575.4 million (Q3 2025), per Business Quant data.